Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Blood

• Publication date

  2015-08-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2014-12-616250PMID 26019278
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How I treat myelofibrosis.

  2014cited by this paper
• Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease.

  2014cited by this paper
• Hemolysis-induced lethality involves inflammasome activation by heme

  2014cited by this paper
• Autologous transfusion of stored red blood cells increases pulmonary artery pressure.

  2014cited by this paper
• Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.

  2014cited by this paper
• Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia

  2014cited by this paper
• Intravascular Hemolysis: A Disease Mechanism Not to Be Ignored

  2014cited by this paper
• Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

  2013cited by this paper
• Therapeutic Approaches to Limit Hemolysis-Driven Endothelial Dysfunction: Scavenging Free Heme to Preserve Vasculature Homeostasis

  2013cited by this paper
• Hemopexin Therapy Improves Cardiovascular Function by Preventing Heme-Induced Endothelial Toxicity in Mouse Models of Hemolytic Diseases

  2013cited by this paper
• HU for acute treatment of sickle VOC?

  2012cited by this paper
• Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study

  2012cited by this paper
• Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

  2012influential reference
• Front-line therapy in polycythemia vera and essential thrombocythemia.

  2012cited by this paper
• Pathological Conditions Involving Extracellular Hemoglobin: Molecular Mechanisms, Clinical Significance, and Novel Therapeutic Opportunities for α1-Microglobulin

  2012cited by this paper
• Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?

  2011cited by this paper
• Hydroxyurea enhances SMN2 gene expression through nitric oxide release

  2011cited by this paper
• Exogenous, but not Endogenous Nitric Oxide Inhibits Adhesion Molecule Expression in Human Endothelial Cells

  2011cited by this paper
• P‐Selectin Mediates the Microvascular Dysfunction Associated with Persistent Cytomegalovirus Infection in Normocholesterolemic and Hypercholesterolemic Mice

  2011cited by this paper
• The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up

  2010cited by this paper
• Strategies to improve efficacy and safety of a novel class of antiviral hyper‐activation‐limiting therapeutic agents: the VS411 model HIV/AIDS

  2010cited by this paper
• Interactions of hemin with model erythrocyte membranes.

  2010cited by this paper
• How I use hydroxyurea to treat young patients with sickle cell anemia.

  2010cited by this paper
• Heme Degradation and Vascular Injury

  2010cited by this paper
• Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death

  2009cited by this paper
• Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria.

  2009cited by this paper
• Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation

  2008cited by this paper
• human erythroid cells Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in

  2008cited by this paper
• Sickle cell disease vasculopathy: a state of nitric oxide resistance.

  2008cited by this paper
• Dose translation from animal to human studies revisited

  2007cited by this paper
• Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion.

  2007cited by this paper
• Heme Induces Neutrophil Migration and Reactive Oxygen Species Generation through Signaling Pathways Characteristic of Chemotactic Receptors*

  2007cited by this paper
• Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease.

  2006cited by this paper
• Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.

  2006cited by this paper
• The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

  2005cited by this paper
• Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin.

  2005cited by this paper
• Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice.

  2004cited by this paper
• Nitric oxide production from hydroxyurea.

  2004influential reference
• Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface.

  2003cited by this paper
• Binding of ovarian steroids to erythrocytes in patients with sickle cell disease; effects on cell sickling and osmotic fragility.

  2003cited by this paper
• Neutrophil activation by heme: implications for inflammatory processes.

  2002cited by this paper
• Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

  2002cited by this paper
• Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm

  2002influential reference
• Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease

  2002cited by this paper
• Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface

  2001cited by this paper
• Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea

  2000cited by this paper
• Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea.

  1999cited by this paper
• Induction of acute inflammatory lung injury by staphylococcal enterotoxin B.

  1997cited by this paper
• Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent

  1996cited by this paper
• Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

  1995cited by this paper
• Methods for measuring plasma hemoglobin in micromolar concentration compared.

  1992cited by this paper
• Treatment of sickle cell anemia with hydroxyurea and erythropoietin.

  1990cited by this paper
• Endothelium‐Derived Relaxing Factor From Pulmonary Artery and Vein Possesses Pharmacologic and Chemical Properties Identical to Those of Nitric Oxide Radical

  1987cited by this paper

• Caspase-1 Activation Drives Vascular Inflammatory Processes and Hypoperfusion in Intravascular Hemolysis.

  2025cites this paper
• Hydroxyurea for Children with Sickle Cell Disease: A Practical Guide for Pediatric Clinicians.

  2025cites this paper
• Acoustic probing of new biomarkers for rapid sickle cell disease screening.

  2025cites this paper
• Pathophysiology of Beta-Thalassaemia: (Part – 2) [Chronic Anaemia/Hypoxia]

  2025cites this paper
• Hydroxyurea Mitigates Heme-Induced Inflammation and Kidney Injury in Humanized Sickle Cell Mice

  2025cites this paper
• Acute intravascular haemolysis rapidly shifts the balance of angiogenic factors and accelerates neovascularization in vivo

  2025cites this paper
• Cell-Free Hemoglobin in the Pathophysiology of Trauma: A Scoping Review

  2024cites this paper
• Targeting P-selectin and interleukin-1b in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition

  2024cites this paper
• Current and emerging drug treatment strategies to tackle sickle cell anemia

  2024cites this paper
• Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target

  2024cites this paper
• The Role of Inflammation in The Cellular and Molecular Mechanisms of Cardiopulmonary Complications of Sickle Cell Disease

  2023cites this paper
• Primary autoimmune haemolytic anaemia is associated with increased risk of ischaemic stroke: A binational cohort study from Denmark and France

  2023cites this paper
• Molecular and cellular effects of in vivo chronic intravascular hemolysis and anti-inflammatory therapeutic approaches.

  2023cites this paper
• Hydroxyurea as a promising ADAM17 inhibitor

  2023cites this paper
• HbS promotes TLR4-mediated monocyte activation and pro-inflammatory cytokine production in sickle cell disease.

  2022cites this paper
• Oxidative Reactions Catalyzed by Hydrogen Peroxide Produced by Streptococcus pneumoniae and Other Streptococci Cause the Release and Degradation of Heme from Hemoglobin

  2022cites this paper
• Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso‐occlusive episodes during the randomized, open‐label HELPS study

  2022cites this paper
• Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.

  2021cites this paper
• Hydroxyurea treatment of sickle cell disease: towards a personalized model-based approach

  2021cites this paper
• VCAM1, HMOX1 and NOS3 differential endothelial expression may impact sickle cell anemia vasculopathy.

  2021cites this paper
• Impact of hydroxyurea on lymphocyte subsets in children with sickle cell anemia

  2021cites this paper
• Optical Imaging Agents

  2021cites this paper
• Heme induces significant neutrophil adhesion in vitro via an NFκB and reactive oxygen species-dependent pathway

  2021cites this paper
• Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso‐occlusion and nephropathy in mouse models of sickle cell disease

  2021cites this paper
• Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease

  2021cites this paper
• Macrophage metabolic adaptation to heme detoxification involves CO-dependent activation of the pentose phosphate pathway.

  2020cites this paper
• Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease

  2020cites this paper
• Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab

  2020cites this paper
• Didox (3,4-dihydroxybenzohydroxamic acid) reduces the vascular inflammation induced by acute intravascular hemolysis.

  2020cites this paper
• Vínculo entre el estrés oxidativo y las anemias hemolíticas: una visión molecular

  2020cites this paper
• Nitric oxide and sickle cell disease—Is there a painful connection?

  2020cites this paper
• Hydroxyurea Scavenges Free Radicals and Induces the Expression of Antioxidant Genes in Human Cell Cultures Treated With Hemin

  2020cites this paper
• Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies

  2020cites this paper
• Intravascular hemolysis triggers ADP-mediated generation of platelet-rich thrombi in pre-capillary pulmonary arterioles.

  2020cites this paper
• Current perspectives of sickle cell disease in Nigeria: changing the narratives

  2019cites this paper
• Pathophysiology of Sickle Cell Disease.

  2019cites this paper
• Oxidized hemoglobin forms contribute to NLRP3 inflammasome-driven IL-1β production upon intravascular hemolysis.

  2019cites this paper
• cGMP modulation therapeutics for sickle cell disease

  2019cites this paper
• Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature

  2019cites this paper
• S100A8 acts as an autocrine priming signal for heme‐induced human Mϕ pro‐inflammatory responses in hemolytic inflammation

  2019cites this paper
• Attenuation of TNF‐induced neutrophil adhesion by simvastatin is associated with the inhibition of Rho‐GTPase activity, p50 activity and morphological changes

  2018cites this paper
• Inflammation in sickle cell disease

  2018cites this paper
• Emerging pharmacotherapeutic approaches for the management of sickle cell disease

  2018cites this paper
• Therapeutic strategies for sickle cell disease: towards a multi-agent approach

  2018cites this paper
• A reappraisal of the mechanisms underlying the cardiac complications of sickle cell anemia

  2017cites this paper
• Heme Protein Metabolism of NO and Nitrite

  2017cites this paper
• Potential therapeutic action of nitrite in sickle cell disease

  2017cites this paper
• TNF induces neutrophil adhesion via formin‐dependent cytoskeletal reorganization and activation of β‐integrin function

  2017cites this paper
• Telomere length correlates with disease severity and inflammation in sickle cell disease

  2017cites this paper
• Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention

  2017cites this paper
• Acute Chest Syndrome in Children with Sickle Cell Disease

  2017cites this paper
• Intravascular hemolysis and the pathophysiology of sickle cell disease

  2017cites this paper
• The Defective Arginine-Nitric Oxide Pathway in Sickle Cell Disease

  2017cites this paper
• Simvastatin reduces vaso‐occlusive pain in sickle cell anaemia: a pilot efficacy trial

  2017cites this paper
• Targeting novel mechanisms of pain in sickle cell disease.

  2017cites this paper
• Targeting novel mechanisms of pain in sickle cell disease.

  2017cites this paper
• A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy

  2017cites this paper
• HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics

  2017cites this paper
• Cellular therapy for sickle cell disease.

  2016cites this paper
• KEY POINTS Red blood abnormalities continue to underlie the complex pathophysiology of SCD

  2016cites this paper
• Sickle-cell disease 3 Cardiovascular complications and risk of death in sickle-cell disease

  2016cites this paper
• Cardiovascular Adaptations to Anemia and the Vascular Endothelium in Sickle Cell Disease Pathophysiology

  2016cites this paper
• Inflammation and sickle cell anemia

  2016cites this paper
• Leg Ulceration in Sickle Cell Disease: An Early and Visible Sign of End‐Organ Disease

  2016cites this paper
• Inflammatory targets of therapy in sickle cell disease.

  2016cites this paper
• A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease

  2016cites this paper
• Minireview: Genetic basis of heterogeneity and severity in sickle cell disease

  2016cites this paper
• Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.

  2016cites this paper
• Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study

  2016cites this paper
• The heart in sickle cell disease, a model for heart failure with preserved ejection fraction

  2016cites this paper
• New insights into sickle cell disease: mechanisms and investigational therapies

  2016cites this paper
• Cardiovascular complications and risk of death in sickle-cell disease.

  2016cites this paper
• Red cell DAMPs and inflammation

  2016cites this paper
• Management of Sickle Cell Disease in Children

  2016cites this paper
• Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?

  2015influential citation
• TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, randomised controlled trial

  2015cites this paper
• Revisiting the hyperhemolysis paradigm.

  2015cites this paper
• Hemolytic vascular inflammation: an update

  2015cites this paper
• President ’ s Column Leading the Charge for Precision Medicine

  year unknowncites this paper